| Literature DB >> 26900635 |
Thomas Deleuran1,2, Søren Overgaard3, Hendrik Vilstrup1, Peter Jepsen1,2.
Abstract
Background and purpose - There are limited data on risk factors for avascular necrosis of the hip, but cirrhosis has been proposed as a risk factor. We examined the association between cirrhosis and incidence of total hip arthroplasty for avascular necrosis. Methods - We used nationwide healthcare data to identify all Danish residents diagnosed with cirrhosis in 1994-2011, and matched them 1:5 by age and sex to non-cirrhotic reference individuals from the general population. We excluded people with a previous total hip arthroplasty, a previous hip fracture, or a previous diagnosis of avascular necrosis. We used stratified Cox regression to estimate the hazard ratio (HR) for cirrhosis patients relative to reference individuals, adjusting for potential confounders. We used the cumulative incidence function to compute 5-year risks. Results - We included 25,421 cirrhosis patients and 114,052 reference individuals. Their median age was 57 years, and 65% were men. 45 cirrhosis patients and 44 reference individuals underwent total hip arthroplasty for avascular necrosis. Cirrhosis patients' HR for a total hip arthroplasty for avascular necrosis was 10 (95% CI: 6-17), yet their 5-year risk of avascular necrosis was only 0.2%. For the reference individuals, the 5-year risk was 0.02%. Interpretation - Cirrhosis is a strong risk factor for avascular necrosis of the hip, but it is rare even in cirrhosis patients.Entities:
Mesh:
Year: 2016 PMID: 26900635 PMCID: PMC4900083 DOI: 10.3109/17453674.2016.1151122
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Prevalence of risk factors for AVN at the index date, with ICD-8 and ICD-10 codes
| ICD-8 | ICD-10 | Cirrhosis patients (%) | Reference individuals (%) | |
|---|---|---|---|---|
| Conditions predisposing to AVN | ||||
| Diabetes mellitus | 249.xx, 250.xx | E10.x–E14.x | 13 | 4 |
| HIV | 079.83 | B20.x–B24.x | 0.26 | 0.06 |
| Myeloproliferative disease | 20x.xx | C88.x, C90–96.x | 0.71 | 0.33 |
| Hemoglobinopathy | 282.xx | D55.x– D59.x | 0.36 | 0.05 |
| Chronic renal failure | 58x.xx | N18.x | 1.2 | 0.37 |
| Gout | 274.0x | M10.x | 2.1 | 0.49 |
| Solid organ transplantation | Y95.xx | Z94.x | 0.28 | 0.15 |
| Indicator of smoking | ||||
| Chronic obstructive lung disease | 490.xx–492.xx | J43.x–J44.x | 7.2 | 2.4 |
| Indicator of corticosteroid treatment | ||||
| Autoimmune hepatitis | 573.02 | K73.2, K75.4 | 0.90 | 0.02 |
| Rheumatoid arthritis | 712.0x–712.2x | M05.x | 0.56 | 0.44 |
| Connective tissue disease | 734.xx | M3x.x | 0.73 | 1.2 |
Results of the main regression analysis and the supplementary regression analysis
| No. of cirrhosis patients (with AVN) | No. of reference individuals (with AVN) | Unadjusted HR | Adjusted HR | |
|---|---|---|---|---|
| Main analysis | 23,421 (45) | 114,052 (44) | 9.9 (5.8–17) | 10 (5.8–17) |
| Supplementary analysis | 4,977 (9) | 21,851 (11) | 13 (3.5–48) | 12 (3.3–47) |
Unadjusted hazard ratio of THA for AVN in cirrhosis patients vs. reference individuals
Adjusted hazard ratio of THA for AVN in cirrhosis patients vs. reference individuals, adjusted for other risk factors for AVN; see Table 1.